Drug intelligence / Profile preview

OXU-003

Development stage: Discontinued
Lead developer: Regeneron Pharmaceuticals
Modality: Small Molecules
Administration: Intraocular, Suprachoroidal

Overview

OXU-003 is a small molecule drug developed by Oxular as a novel treatment for retinoblastoma and other serious sight-threatening ocular diseases. It utilizes Oxular's proprietary sustained-release formulation and ocular administration technology, designed to deliver precise, long-lasting therapeutic effects directly to the eye. The drug has received both Rare Pediatric Disease and Orphan Drug designations from the FDA for retinoblastoma. While it was planned for advancement into phase 2 clinical studies, its development status is now listed as discontinued at the preclinical stage. The specific molecular target or mechanism of action has not been publicly disclosed[1][2][4].

Brand names: OXU-003OXU003OXU 003
Other names: OXU-003OXU003OXU 003

Beyond the preview

Go deeper on OXU-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXU-003.

Explore the full profile